Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cantuzumab mertansine

Drug Profile

Cantuzumab mertansine

Alternative Names: C-242 DM1; C-242 May; C242 maytansinoid conjugate; huC242 maytansinoid conjugate; huC242-DM1; Monoclonal antibody C-242 DM1 conjugate; Monoclonal antibody C-242 May conjugate; Monoclonal antibody huC242-May conjugate; SB-408075

Latest Information Update: 17 Jan 2005

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunoGen
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Maytansinoids; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 17 Jan 2005 Discontinued - Phase-I for Cancer in USA (unspecified route)
  • 04 Apr 2003 Clinical data from a media release have been added to the Cancer pharmacodynamics section
  • 24 Jan 2003 ImmunoGen regained rights for cantuzumab mertansine from GlaxoSmithKline
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top